Advent and Warburg Pincus completed the acquisition of the BioPharma Solutions business of Baxter for $4.25bn.

Advent International and Warburg Pincus, two private equity investors, completed the acquisition of the BioPharma Solutions business of Baxter, a global medtech company, for $4.25bn. “Today represents an important step in Baxter’s ongoing transformation journey as we continue to execute against our strategic priorities, enhance our focus and create additional value for all our stakeholders. BPS has long been recognized worldwide as a trusted and preferred partner of contract manufacturing services for the pharmaceutical and biotech industries. Advent International and Warburg Pincus have extensive experience helping innovative healthcare companies advance their mission and strategic priorities. I am confident that under their stewardship, BPS will continue to build on its leadership position, foster world-class talent, invest in new capabilities and capacity, and provide leading-edge, high-quality solutions for its clients," José E. Almeida, Baxter Chairman, President and CEO.